Cerecor Announces Initiation of Phase 2 Clinical Trial With CERC-501 for SmokingCessation

Cerecor Inc. (CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients
with neurological and psychiatric disorders, today announced that
the Company has enrolled its first subject in the Phase 2 clinical
trial for CERC-501, “A Randomized, Double-Blind, Placebo-Controlled,
Cross-over Design Study of CERC-501 in a Human Laboratory Model
of Smoking Behavior”.

This entry was posted in Recent Developments. Bookmark the permalink.
Read Full Article »